Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

被引:111
作者
Mehta, Shruti H.
Lucas, Gregory M.
Mirel, Lisa B.
Torbenson, Michael
Higgins, Yvonne
Moore, Richard D.
Thomas, David L.
Sulkowski, Mark S.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Sch Publ Hlth, Baltimore, MD USA
关键词
HIV; hepatitis C; referral; intravenous drug abuse; antiviral therapy;
D O I
10.1097/QAD.0b013e32801086da
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate predictors and trends of referral for hepatitis C virus (HCV) care, clinic attendance and treatment in an urban HIV clinic. Design and methods: A retrospective cohort analysis in which 845 of 1318 co-infected adults who attended the Johns Hopkins HIV clinic between 1998 and 2003 after an on-site viral hepatitis clinic was opened, attended regularly (>= 1 visit/year for >= 2 years). Logistic regression was used to examine predictors of referral. Results: A total of 277 (33%) of 845 were referred for HCV care. Independent predictors of referral included percentage elevated alanine aminotransferase levels [adjusted odds ratio (AOR) for 10% increase,1.16; 95% confidence interval (CI), 1.10-1.22] and CD4 cell count > 350 cells/mu l (AOR, 3.20; 95% CI, 2.10-4.90), while injection drug use was a barrier to referral (AOR, 0.26; 95% CI, 0.11-0.64). Overall referral rate increased from < 1% in 1998 to 28% in 2003; however, even in 2003, 65% of those with CD4 cell count > 200 cells/mu l were not referred. One hundred and eighty-five (67%) of 277 referred kept their appointment, of whom 32% failed to complete a pre-treatment evaluation. Of the remaining 125, only 69 (55%) were medically eligible for treatment, and 29 (42%) underwent HCV treatment. Ninety percent of 29 were infected with genotype 1 and 70% were African American; six (21%) achieved sustained virologic response (SVR). Only 0.7% of the full cohort achieved SVR. Conclusions: Although the potential for SVR and the recent marked increase in access to HCV care are encouraging, overall effectiveness of anti-HCV treatment in this urban, chiefly African American, HCV genotype 1 HIV clinic is extremely low. New therapies and treatment strategies are an urgent medical need. (c) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:2361 / 2369
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[2]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[3]  
BOBBOLA M, 2005, AM COLL GASTR 70 ANN
[4]   Reasons for non-treatment of hepatitis C in veterans in care [J].
Butt, AA ;
Wagener, M ;
Shakil, AO ;
Ahmad, J .
JOURNAL OF VIRAL HEPATITIS, 2005, 12 (01) :81-85
[5]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[6]   Surprisingly small effect of antiviral treatment in patients with hepatitis C [J].
Falck-Ytter, Y ;
Kale, H ;
Mullen, KD ;
Sarbah, SA ;
Sorescu, L ;
McCullough, AJ .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (04) :288-292
[7]   Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection [J].
Fishbein, DA ;
Lo, YT ;
Reinus, JF ;
Gourevitch, MN ;
Klein, RS .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (03) :1367-1375
[8]   Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care [J].
Fleming, CA ;
Tumilty, S ;
Murray, JE ;
Nunes, D .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S349-S354
[9]   Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment [J].
Fleming, CA ;
Craven, DE ;
Thornton, D ;
Tumilty, S ;
Nunes, D .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :97-100
[10]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982